PPF ("PMG Partners Funds") - PMG Global Biotech Fund I

Reference Data

ISIN LU0426487442
Valor Number 10173746
Bloomberg Global ID BBG000LZWTW4
Fund Name PPF ("PMG Partners Funds") - PMG Global Biotech Fund I
Fund Provider PMG Investment Solutions AG Zug, Schweiz
Phone: +41 44 215 28 38
E-Mail: pmg@pmg.swiss
Web: https://www.pmg.swiss
Fund Provider PMG Investment Solutions AG
Representative in Switzerland PMG Investment Solutions AG
Zug
Phone: +41 44 215 28 38
Distributor(s) PMG Investment Solutions AG
Zug
Phone: +41 44 215 28 38
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The objective of the investment policy of the Subfund is to achieve the highest possible long-term capital growth in US dollars by taking advantage of the opportunities offered by biotech and pharmaceutical shares on the global stock markets. This involves investing in listed shares of companies that specialise in the identification, development and production of innovative chemical products for the healthcare sector. To achieve the investment objectives, the subfund will primarily invest in equities and, in part, in futures and exchange-traded options. The country-specific focus of the Fund is on the United States, Europe and the Asia region. This focus also includes investments in emerging markets in Europe and Asia. Investments are made in securities irrespective of their market capitalisation (small cap, mid cap, large cap). Up to 10% of the assets of the subfund may also be invested in China Connect Securities via the Stock Connect Programme.
Peculiarities

Fund Prices

Current Price * 86.63 USD 17.12.2024
Previous Price * 86.60 USD 16.12.2024
52 Week High * 95.45 USD 21.08.2024
52 Week Low * 79.03 USD 18.04.2024
NAV * 86.63 USD 17.12.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 17,156,231
Unit/Share Assets *** 12,415,746
Trading Information SIX

Performance

YTD Performance -1.01% 29.12.2023
17.12.2024
YTD Performance (in CHF) +5.01% 29.12.2023
17.12.2024
1 month +3.05% 18.11.2024
17.12.2024
3 months -7.90% 17.09.2024
17.12.2024
6 months -0.69% 17.06.2024
17.12.2024
1 year +2.34% 18.12.2023
17.12.2024
2 years -6.32% 19.12.2022
17.12.2024
3 years -32.11% 17.12.2021
17.12.2024
5 years -22.46% 17.12.2019
17.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

SIGA Technologies Inc 6.71%
Regeneron Pharmaceuticals Inc 5.23%
Amgen Inc 5.06%
Moderna Inc 4.84%
Vertex Pharmaceuticals Inc 3.65%
Biogen Inc 3.60%
Illumina Inc 3.60%
Chimerix Inc 3.51%
BioNTech SE ADR 3.31%
Seagen Inc Ordinary Shares 2.86%
Last data update 31.08.2022

Cost / Risk

TER 2.12%
TER date 30.06.2024
Performance Fee *** 20.00%
PTR
Max. Management Fee *** 1.20%
Ongoing Charges *** 1.70%
SRRI ***
SRRI date *** 30.11.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)